Cetera Investment Advisers
HAE icon

Cetera Investment Advisers’s Haemonetics HAE Stock Holding History

Cetera Investment Advisers’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,324
Closed -$276K – 1645
2020
Q4 		$276K Buy
+2,324
New +$250K 0.01% 1284

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cetera Investment Advisers's HAE Position: Q1 2021 in Review

Cetera Investment Advisers sold out of Haemonetics (HAE) in Q1 2021, closing a stake of 2,324 shares — an estimated $276K sold.

Cetera Investment Advisers first reported a position in HAE in Q4 2020 and held it in 1 quarter. The position peaked at $276K in Q4 2020. 296 funds tracked by Wall St. Rank hold HAE as of Q1 2021.

  • Cetera Investment Advisers reported no remaining Haemonetics position as of Q1 2021 after selling out during the quarter.
  • Cetera Investment Advisers sold 2,324 Haemonetics shares in Q1 2021, an estimated $276K.
  • Cetera Investment Advisers first reported a position in Haemonetics in Q4 2020 and held it in 1 quarter.
  • Cetera Investment Advisers's Haemonetics position peaked at $276K in Q4 2020.
  • 296 funds tracked by Wall St. Rank held Haemonetics as of Q1 2021.

Based on Cetera Investment Advisers's 13F filing for Q1 2021, filed 17 May 2021.